22nd Century Applauds FDA Proposal to Mandate Reduced Nicotine Content in Cigarettes
22nd Century Applauds FDA Proposal to Mandate Reduced Nicotine Content in Cigarettes
Recent FDA Action Advances Policy Proposal That Originated During First Trump Administration and Continued to Progress Under Biden Administration
最近FDA的行動推動了在特朗普首任政府期間提出的政策提案,並在拜登政府下持續推進。
Mocksville, North Carolina--(Newsfile Corp. - December 12, 2024) - 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, today announced that it applauds action by the U.S. Food and Drug Administration to advance its long-standing proposal mandating a drastic reduction in the amount of nicotine in cigarettes, a cornerstone goal of public health experts seeking to reduce the harms of smoking.
北卡羅來納州莫克斯維爾--(Newsfile CORP. - 2024年12月12日) - 22nd Century Group, Inc. (納斯達克: XXII),一家菸草製品公司,致力於與尼古丁作鬥爭,並認爲吸菸者應該對其尼古丁消費有選擇權,今天宣佈,對美國食品和藥物管理局推動其長期提案表示讚賞,該提案要求大幅減少香菸中的尼古丁含量,這是公共衛生專家尋求減少吸菸危害的核心目標。
"We are excited to see definitive action by the FDA intended to advance its scientifically backed reduced nicotine content mandate for cigarette products, a non-partisan proposal that actually began moving forward during the first Trump administration and continued its progress during the Biden administration," said Larry Firestone, Chief Executive Officer of 22nd Century Group.
22nd Century的首席執行官拉里·法爾斯通表示:"我們很高興看到FDA採取明確行動推動其基於科學的香菸產品低尼古丁含量法規,這是一個跨黨派的提案,實際上是在特朗普首任政府期間開始推進的,並在拜登政府期間繼續取得進展。"
"22nd Century has played a pivotal role in this effort following 26 years of research and product development as a key supplier for reduced nicotine content research cigarettes used in the numerous federally funded studies to generate a massive body of scientific evidence in support of this policy. 22nd Century also has the first and only FDA authorized reduced nicotine content cigarette designed specifically to reduce the harms of smoking."
"22nd Century在這項工作中發揮了關鍵作用,經過26年的研究和產品開發,作爲低尼古丁含量研究香菸的主要供應商,參與了衆多聯邦資助的研究,生成了大量科學證據支持該政策。22nd Century還擁有第一個也是唯一一個FDA授權的低尼古丁含量香菸,專門設計用於減少吸菸的危害。"
"VLN reduced nicotine content cigarettes from 22nd Century, which are available in thousands of stores across the country, have shown that this product can be an important tool for adult smokers seeking to control their nicotine intake. We are now in the process of launching additional products, including VLN SKUs within key customer brand families, as part of our drive to expand the distribution of reduced nicotine content cigarettes manufactured by 22nd Century. Adding VLN within other brand families is a straightforward way to reduce our time to market, increase consumer awareness and expand the VLN footprint.
"22nd Century的VLN低尼古丁含量香菸在全國數千家商店都有銷售,已經證明該產品可以成爲成人吸菸者控制尼古丁攝入的重要工具。我們現在正在推出更多產品,包括在關鍵客戶品牌系列中推出的VLN SKU,作爲擴大22nd Century生產的低尼古丁含量香菸分銷的努力的一部分。在其他品牌系列中增加VLN是一種簡單的方式,可以縮短我們的市場時間,增加消費者意識,並擴大VLN的影響。"
"With still almost half a million premature deaths in the U.S. attributed to smoking each year, we fully support the FDA in advocating for the significant potential harm reduction that could come from a reduced nicotine content cigarette mandate."
「在美國,每年因吸菸導致的過早死亡人數仍接近五十萬,我們全力支持FDA倡導減少尼古丁含量香菸法規可能帶來的顯著潛在危害降低。」
About 22nd Century Group, Inc.
關於22nd Century Group, Inc.
22nd Century Group is the pioneering nicotine harm reduction company in the tobacco industry enabling smokers to take control of their nicotine consumption.
22nd Century Group是菸草行業中開創性的尼古丁危害減少公司,幫助吸菸者控制他們的尼古丁消費。
We created our flagship product, the VLN cigarette, to give traditional cigarette smokers an authentic and familiar alternative that helps them take control of their nicotine consumption. VLN cigarettes have 95% less nicotine than the traditional cigarette and have been proven to greatly reduce nicotine consumption. Instead of offering new ways of delivering nicotine to addicted smokers, we offer smokers the option to take control of their nicotine consumption and make informed and more productive choices, including the choice to avoid addictive levels of nicotine altogether.
我們創造了我們的旗艦產品VLN香菸,爲傳統香菸吸菸者提供一種真實且熟悉的替代選擇,幫助他們 控制他們的尼古丁消費。VLN香菸的尼古丁含量比傳統香菸低95%,並已被證明能大大減少尼古丁消費。我們不是爲上癮的吸菸者提供新的尼古丁輸送方式,而是爲吸菸者提供控制他們的尼古丁消費、做出知情且更有效選擇的機會,包括選擇完全避免上癮水平的尼古丁。
Our wholly owned subsidiaries include a leading cigarette manufacturer that produces all VLN products and provides turnkey contract manufacturing for other tobacco brands both domestically and internationally. The 60,000 square foot facility in Mocksville, North Carolina has the capacity to produce more than 45 million cartons of combusted tobacco products annually with additional space for expansion.
我們的全資子公司包括一家領先的香菸製造商,生產所有VLN產品,併爲其他菸草品牌提供交鑰匙合同製造服務,涵蓋國內和國際市場。位於北卡羅來納州莫克斯維爾的6萬平方英尺的設施每年可以生產超過4500萬箱燃燒菸草製品,並有額外空間用於擴展。
Our proprietary reduced nicotine tobacco blends are made possible by comprehensive and patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, resulting in full flavor and high yield with 95% less nicotine. Our extensive patent portfolio has been developed to ensure we have the only low nicotine combustible cigarette in the United States and critical international markets.
我們的專有低尼古丁菸草混合物得益於授權技術,調節菸草植物中尼古丁生物合成活性,最終實現95%低尼古丁的全面風味和高產量。我們的廣泛專利組合旨在確保我們在美國及關鍵國際市場上擁有唯一的低尼古丁可燃香菸。
VLN and Helps You Smoke Less are registered trademarks of 22nd Century Limited LLC.
VLN和降低吸菸量的Helps You Smoke Less是22nd century Limited LLC的註冊商標。
Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.
了解更多請訪問 xxiicentury.com,在 X(前身爲Twitter),在 LinkedIn,並且在 YouTube.
Learn more about VLN at tryvln.com.
了解更多關於VLN的信息。 tryvln.com.
Cautionary Note Regarding Forward-Looking Statements
關於前瞻性聲明的警示說明
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024, and in the Company's Quarterly Reports filed on May 15, 2024 and August 13, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.
除了歷史信息之外,本文稿中的所有陳述、預期和假設都是前瞻性陳述,包括但不限於我們全年的業務展望。前瞻性陳述通常包含諸如「預計」、「相信」、「考慮」、「繼續」、「可能」、「估計」、「期待」、「探討」、「預測」、「目標」、「指導」、「意圖」、「可能」、「可能」、「計劃」、「潛在」、「預測」、「初步」、「可能」、「項目」、「有希望」、「尋求」、「應該」、「將會」、「會」等類似表達。前瞻性陳述包括但不限於關於(i)我們成本削減舉措的陳述,(ii)對監管執行的預期,包括我們獲得新規豁免的能力,(iii)我們的財務和運營表現以及(iv)我們對業務中斷保險索賠的預期。實際結果可能與前瞻性陳述中明確或隱含的內容有重大差異。可能導致實際結果與前瞻性陳述有重大差異的重要因素在於2024年3月28日提交的公司年度報告(表格10-k)中的「風險因素」部分,以及在2024年5月15日和2024年8月13日提交的公司季度報告中。本文稿中提供的所有信息均爲截至本日期的信息,公司不承擔任何義務,也不打算更新這些前瞻性陳述,除非法律要求。
Investor Relations & Media Contact
投資者關係與媒體聯繫方式
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200
馬特·克雷普斯
投資者關係
22世紀集團
mkreps@xxiicentury.com
214-597-8200
譯文內容由第三人軟體翻譯。